Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15100887 | 1.00 | EPHX2 (0.42) | EPHX2L3MBTL1APPNPC1RAB9A | |
| SCHEMBL14869879 | 0.92 | HPGD (0.43) | L3MBTL1CYP1A2CYP2D6CYP2C19MEN1 | |
| SCHEMBL14870299 | 0.89 | EPHX2 (0.42) | EPHX2L3MBTL1APPNPC1RAB9A | |
| SCHEMBL14870275 | 0.86 | TAAR1 (0.41) | L3MBTL1TAAR1SMN1; SMN2LMNAHTR1A | |
| SCHEMBL14869884 | 0.85 | APP (0.41) | APPSMN1; SMN2GAA | |
| SCHEMBL14870250 | 0.84 | TAAR1 (0.47) | TAAR1ALDH1A1SMN1; SMN2HTR1AMAOA | |
| SCHEMBL14869899 | 0.84 | TAAR1 (0.43) | EPHX2L3MBTL1APPNPC1RAB9A | |
| SCHEMBL14872424 | 0.82 | CAPN1 (0.34) | HTR1A | |
| SCHEMBL14869777 | 0.81 | CNR2 (0.33) | HTR1A | |
| SCHEMBL14870196 | 0.81 | TAAR1 (0.37) | TAAR1HTR1AADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2941245-B1 | DELAYED-RELEASE COMPOSITION COMPRISING BIGUANIDE | ANJI PHARMACEUTICALS INC (US) | 2024-06-26 | — | — | EP | disclosed |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230285330-A9 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | ANJI PHARMACEUTICALS INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230285330-A9 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | ANJI PHARMACEUTICALS INC. | 2023-09-14 | — | — | US | disclosed |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ANJI PHARMACEUTICALS INC. | 2022-05-19 | — | — | US | disclosed |
| US-11065215-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMA (US) LLC (US) | 2021-07-20 | — | — | US | disclosed |
| EP-2800561-B1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ANJI PHARMA US LLC (US) | 2020-08-19 | — | — | EP | disclosed |
| US-10668031-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMA (US) LLC (US) | 2020-06-02 | — | — | US | disclosed |
| US-20200138751-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2020-05-07 | — | — | US | disclosed |
| WO-2014107617-A1 | DELAYED-RELEASE COMPOSITION COMPRISING BIGUANIDE | ELCELYX THERAPEUTICS, INC. (US) | 2014-07-10 | — | — | WO | disclosed |
| US-20140193498-A1 | Compositions and Methods for Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2014-07-10 | — | — | US | disclosed |
| US-20140193498-A1 | Compositions and Methods for Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2014-07-10 | — | — | US | disclosed |
| WO-2014011926-A1 | COMPOSITIONS COMPRISING STATINS, BIGUANIDES AND FURTHER AGENTS FOR REDUCING CARDIOMETABOLIC RISK | ELCELYX THERAPEUTICS, INC. (US) | 2014-01-16 | — | — | WO | disclosed |
| US-20130177604-A1 | Compositions and Methods of Treating Metabolic Disorders | ELCELYX THERAPEUTICS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130177604-A1 | Compositions and Methods of Treating Metabolic Disorders | ELCELYX THERAPEUTICS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| WO-2013103384-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ELCELYX THERAPEUTICS, INC. (US) | 2013-07-11 | — | — | WO | disclosed |
| WO-2013103919-A2 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | ELCELYX THERAPEUTICS, INC. (US) | 2013-07-11 | — | — | WO | disclosed |
| US-20130095140-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ELCELYX THERAPEUTICS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130095140-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ELCELYX THERAPEUTICS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10668031-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | EPHX2 1873/4885L3MBTL1 4566/4885APP 2243/4885 |
| US-11065215-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | EPHX2 1873/4885L3MBTL1 4566/4885APP 2243/4885 |
| US-20130095140-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GPR119 | EPHX2 1873/4885L3MBTL1 4566/4885APP 2243/4885 |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | EPHX2 1873/4885L3MBTL1 4566/4885APP 2243/4885 |
| US-20130177604-A1 | Compositions and Methods of Treating Metabolic Disorders | FABP2, GPR119, PNLIP | EPHX2 4097/4885L3MBTL1 2212/4885APP 3836/4885 |
| US-20140193498-A1 | Compositions and Methods for Treating Metabolic Disorders | SLC5A2, SLC10A1, GPR119 | EPHX2 1988/4885L3MBTL1 3611/4885APP 1524/4885 |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | SLC5A2, SLC5A1, GPR119 | EPHX2 1873/4885L3MBTL1 4566/4885APP 2243/4885 |
| US-20230285330-A9 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | FABP2, GPR119, PNLIP | EPHX2 3835/4885L3MBTL1 2663/4885APP 3552/4885 |
| US-20200138751-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GCG | EPHX2 1909/4885L3MBTL1 4487/4885APP 2074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.